Why Farbe Firma is the Top Manufacturer of Diclofenac Potassium Injection
- Maulik Sudani
- 2 days ago
- 9 min read
Last Updated: June 30, 2026
TL;DR: Diclofenac Potassium Injection - a sterile aqueous solution of diclofenac potassium, a potent phenylacetic-acid (arylacetic-acid) NSAID and non-selective inhibitor of cyclo-oxygenase, supplied commonly as a 25 mg/mL solution in a 3 mL ampoule (75 mg/3 mL) given by deep intramuscular injection or, after dilution, by intravenous infusion - is the rapid-onset, non-opioid analgesic clinicians use for the short-term management of acute pain such as post-operative pain, renal and biliary colic, acute musculoskeletal pain and acute exacerbations of arthritis, where the readily soluble potassium salt supports a fast onset of analgesia. Because diclofenac is a poorly water-soluble, oxidation-prone active that must be held in solution by a co-solvent system and protected with an antioxidant, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance profile, the antioxidant and co-solvent control, the controlled pH, clarity, fill volume, low particulate and endotoxin, light protection, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Diclofenac Potassium Injection at our Gujarat, India facility and supplies it to surgical, anaesthesia, pain-management, emergency-medicine and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Phenylacetic-acid (arylacetic-acid) NSAID and non-selective cyclo-oxygenase inhibitor - diclofenac blocks prostaglandin synthesis to control pain and inflammation, and Diclofenac Potassium Injection (25 mg/mL, deep intramuscular or, after dilution, IV infusion) uses the readily soluble potassium salt for a rapid onset and demands an exact, reproducible parenteral dose for the short-term management of acute pain.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and ampoule filling lines, control of the stability-indicating assay, the related-substance profile, the antioxidant and co-solvent system, the controlled pH, clarity, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Diclofenac Potassium Injection Demands a Premium Manufacturer
Diclofenac Potassium Injection occupies a central place in acute-pain and peri-operative practice across every market - diclofenac is among the most widely used NSAIDs in the world. It is the analgesic a clinician reaches for when a patient needs fast, strong, non-opioid relief from acute pain but cannot conveniently take a tablet - in the hours after surgery, during an episode of renal or biliary colic, in an acute musculoskeletal injury or in an acute flare of arthritis. What makes the potassium salt distinctive is its dissolution and absorption: diclofenac potassium is the readily soluble, rapidly absorbed salt of diclofenac - a phenylacetic-acid (arylacetic-acid) derivative and non-selective inhibitor of both cyclo-oxygenase-1 and cyclo-oxygenase-2 - and choosing the potassium salt rather than the slower sodium salt supports a faster onset of analgesia. In a multimodal, opioid-sparing regimen, that combination of a fast onset and diclofenac's well-established anti-inflammatory potency is exactly why diclofenac remains a mainstay of injectable acute-pain control wherever a rapid, dependable non-opioid option is needed. Because the injection is given parenterally, the dose from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Diclofenac Potassium Injection is presented as a ready-to-use sterile solution - for example 75 mg of diclofenac potassium in a 3 mL ampoule, 25 mg/mL, given by deep intramuscular injection or, after dilution, by intravenous infusion - so the assay must be exact and the fill volume accurate so that each unit delivers the labelled content. The defining formulation challenge is twofold: diclofenac is poorly water-soluble, so the bulk solution depends on a carefully designed co-solvent system to hold the active fully in solution; and diclofenac is oxidation-prone and discolours as it degrades, so an antioxidant and a tightly controlled pH are needed to keep the solution clear and near-colourless across shelf life. The active is also light-sensitive, so photostability under ICH Q1B and light-protective processing and packaging matter, and the manufacturer must run a stability-indicating method that resolves and quantifies diclofenac and its related and degradation substances without interference. The right sterilisation route - terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing - must be selected and validated. The NSAID class cautions - the gastrointestinal, renal and the well-documented cardiovascular thrombotic risks that are a particular focus for diclofenac, the risk of serious skin reactions and of hypersensitivity and bronchospasm, and, where a sulfite antioxidant is used, sulfite hypersensitivity - must be clearly carried on the label, along with deep-intramuscular administration technique to limit injection-site reactions. Choosing a Diclofenac Potassium Injection manufacturer that treats the co-solvent system, the antioxidant and pH control, the stability-indicating assay, related-substance control and clarity and particulate and endotoxin control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Diclofenac Potassium Injection Manufacturer Apart
A world-class manufacturer of Diclofenac Potassium Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of diclofenac with related-substance control by validated HPLC, which an oxidation-prone, poorly-soluble NSAID demands; a robust, validated sterilisation and fill process built around a co-solvent-solubilised, antioxidant-protected solution that must stay clear, near-colourless and precipitate-free from compounding through to the point of use; and tender-ready dossier support, including the antioxidant-and-pH, photostability and accelerated stability data, for an analgesic procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial-grade diclofenac potassium sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the entire value of the product depends on the poorly-soluble active staying fully dissolved and the oxidation-prone solution staying clear and near-colourless, the co-solvent, antioxidant and pH design are treated as central evidence rather than supporting annexes.
Compounding and filling then have to defend the assay, the clarity and, above all, the dissolved, non-oxidised state of an oxidation-prone, poorly-soluble active. The bulk solution is compounded in water-for-injection with the co-solvent system and antioxidant at the controlled pH that holds diclofenac fully in solution and resists oxidation, sterile-filtered through a 0.22 micron membrane and filled into ampoules - or vials - under ISO Class 5 conditions, often with inert-gas purging of the solution and headspace and under light protection, with the validated sterilisation route locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity, colour and particulate defects; in-process and release testing confirm the assay of diclofenac by validated HPLC, the related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intramuscular and intravenous administration. Because the active is poorly soluble and oxidation-prone, assay accuracy, related-substance control, pH and antioxidant control and clarity-and-colour are confirmed together so the assay and the clear, near-colourless appearance stay within specification across shelf life, with no precipitation and no oxidative discolouration in the ampoule.
Quality Systems Behind Every Diclofenac Potassium Injection
Every Farbe Firma Diclofenac Potassium Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of diclofenac against pharmacopoeial reference standards, control of related and degradation substances by HPLC, antioxidant content where used, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release. Where the marketed presentation relies on an antioxidant and inert-gas headspace, the effectiveness of that oxidation-control strategy is qualified through stability rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with inert-gas purging and 100 % inspection, light-protected compounding and holding, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because diclofenac potassium is a poorly-soluble, oxidation-prone NSAID given parenterally and the assay, related-substance profile, pH and antioxidant control drive both efficacy and safety, we treat the stability-indicating assay, the related-substance profile, the controlled pH and antioxidant content and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions, with ICH Q1B photostability documented, so the assay, clarity and colour stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Diclofenac Potassium Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad analgesia, anti-inflammatory and peri-operative small-volume parenteral portfolio. For Diclofenac Potassium Injection specifically, we supply the ready-to-use 75 mg/3 mL (25 mg/mL) solution in ampoule and vial presentations under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the co-solvent-and-antioxidant, stability-indicating-assay, related-substance, pH, photostability, sterilisation and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Diclofenac Potassium Injection can request the antioxidant-and-pH and accelerated-stability summaries up front, which is often the deciding technical evidence for an oxidation-prone NSAID solution in hospital-formulary and ministry-of-health review.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork - including deep-intramuscular and intravenous-infusion administration instructions, store-below-30-degrees-C and protect-from-light storage directions, and the gastrointestinal, renal, cardiovascular, serious-skin-reaction, hypersensitivity-and-bronchospasm and (where a sulfite antioxidant is used) sulfite-sensitivity cautions of the NSAID class - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Diclofenac Potassium Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the design of a co-solvent and antioxidant system for an oxidation-prone, poorly-soluble NSAID, the development of a stability-indicating assay, related-substance and degradation control, controlled-pH formulation design, inert-gas and light-protection strategy, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For an oxidation-prone, poorly-soluble NSAID where the co-solvent system, antioxidant and pH control and dose precision directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Diclofenac Potassium Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Diclofenac Potassium Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and ampoule filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Diclofenac Potassium Injection do you supply?
Our standard presentation is the ready-to-use 75 mg/3 mL (25 mg/mL) solution of diclofenac potassium in an ampoule for deep intramuscular injection or, after dilution, intravenous infusion. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Diclofenac Potassium Injection mainly used for?
Diclofenac Potassium Injection is used for the short-term management of acute pain, such as post-operative pain, renal and biliary colic, acute musculoskeletal pain and acute exacerbations of arthritis, when an oral dose is not practical. It is a potent phenylacetic-acid NSAID and non-selective cyclo-oxygenase inhibitor, and the readily soluble potassium salt supports a rapid onset; Farbe Firma verifies the assay, related-substance profile, pH, clarity, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose. It is given by deep intramuscular injection or intravenous infusion, and the gastrointestinal, renal, cardiovascular, serious-skin-reaction and hypersensitivity cautions of the class are carried on the label.
Can Farbe Firma support country-specific registrations for Diclofenac Potassium Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Diclofenac Potassium Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our analgesia and anti-inflammatory small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments